查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2017490

阿茲海默症（AD）：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

Alzheimer's Disease (AD) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 158 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場概覽

  • 阿茲海默症市場正在經歷重大變革，其驅動力是疾病修正治療的出現和廣泛應用。
  • 美國確診患者數量正以 5% 的複合年成長率成長，形成了一個巨大且持續成長的潛在市場。
  • 法國阿茲海默症市場預計將從 2025 年的 2,700 萬美元成長到 2035 年的 9.78 億美元。

阿茲海默症（AD）概述

阿茲海默症（AD）是失智症的主要病因，約佔所有失智症病例的60%至80%。它是進行性神經退化性疾病，其特徵是認知能力下降、記憶力減退和功能衰退，最終導致完全依賴他人照顧。

這種疾病的特徵主要體現在大腦的三個病理特徵：

1. 澱粉樣斑塊 - 由澱粉樣BETA片段組成的細胞外蛋白質聚集體。

2. 神經纖維纏結（NFTs）－細胞內過度磷酸化的Tau蛋白積累

3. 突觸和神經細胞的喪失－這會破壞神經細胞之間的通訊，導致進行性認知能力下降。

這些病理變化將阿茲海默症（AD）與其他失智症（例如路易氏體失智症和血管性失智症）區分開來，儘管其他病理變化也可能同時存在，這種情況被稱為混合型失智症。 AD主要影響老年人，且罹病風險隨年齡增加而顯著增加。臨床上，此疾病會從輕度認知障礙（MCI）進展為中度至重度失智症。

近期的進展已經將治療模式從單純的症狀治療轉變為針對澱粉樣蛋白病理的疾病修正治療（DMT），這代表了阿茲海默症治療前景的重大轉變。

主要亮點

  • 預計到 2025 年，美國阿茲海默症人數將大幅增加至 2035 年的 490 萬人，呈現強勁的成長動能（年複合成長率超過 5%）。
  • 阿茲海默症（AD）仍然是一種負擔沉重的慢性疾病，對臨床、經濟和看護者都有重大影響。
  • 儘管患者數量眾多，但早期診斷仍不足，限制了及時介入和疾病修正治療的引入。
  • 治療模式正從症狀治療（膽鹼酯酶抑制劑、NMDA拮抗劑）轉向針對BETA-澱粉樣蛋白路徑的疾病修正治療。
  • 早期患者（MCI/輕度阿茲海默症）是新興治療方法的主要目標族群，並推動了細分和治療優先順序的確定。

格式化和更新訊息

  • 詳細報告（PDF）
  • 市場預測模型（基於微軟Excel）
  • 流行病學數據（MS Excel，互動式工具）
  • 高階主管洞察（PPT簡報）
  • 其他功能：定期更新、自訂和顧問支援。
  • 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

  • 我們如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
  • 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
  • 未來十年市場收入和病患佔有率的預測是多少？
  • 哪些因素對市場趨勢影響最大？
  • 受訪專家對目前和新興的治療方法有何看法？
  • 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
  • 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
  • 為確保藥物核准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

  • G8
    • 美國
    • EU5
      • 法國
      • 德國
      • 義大利
      • 西班牙
      • 英國
    • 日本
    • 中國

大公司

  • Hoffmann-La Roche
  • Halia Therapeutics, Inc.
  • Novo Nordisk A/S
  • BeyondBio Inc.
  • Ono Pharmaceutical Co. Ltd
  • Eli Lilly and Company
  • Regeneration Biomedical, Inc.
  • Keymed Biosciences Co.Ltd
  • Amydis Inc.
  • ScandiBio Therapeutics AB
  • Karuna Therapeutics, Inc.
  • NSC-Therapeutics
  • Alzamend Neuro, Inc.
  • Annovis Bio Inc.
  • Bristol-Myers Squibb
  • NKGen Biotech, Inc.
  • Acumen Pharmaceuticals
  • Lexeo Therapeutics
  • Eisai Inc.
  • Cassava Sciences, Inc.
  • Merck Sharp &Dohme LLC
  • AriBio Co., Ltd.
  • Alector Inc.
  • Noah Pharmaceuticals, Inc.
  • Amylyx Pharmaceuticals Inc.
  • TauRx Therapeutics Ltd
  • Jiangsu Nhwa Pharmaceutical Co., Ltd.
  • AbbVie
  • Oligomerix, Inc
  • Life Molecular Imaging Ltd
  • Nuravax, Inc.
  • Green Valley（Shanghai）Pharmaceuticals Co., Ltd.
  • Novartis Pharmaceuticals
  • Beijing Joekai Biotechnology LLC
  • Vigil Neuroscience, Inc.
  • Allyx Therapeutics
  • T3D Therapeutics, Inc.
  • GlaxoSmithKline
  • Atridia Pty Ltd.
  • Alnylam Pharmaceuticals
  • Shanghai Hengrui Pharmaceutical Co., Ltd.
  • Akeso
  • Medesis Pharma SA
  • Avid Radiopharmaceuticals
  • CereMark Pharma, LLC
  • Araclon Biotech SL
  • Luye Pharma Group Ltd.

目錄

第1章：主要調查結果及分析師說明

  • 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

  • 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

  • 重點
  • 發病率/盛行率
  • 已確診並接受藥物治療的患者人數
  • 合併症
  • 其他相關患者群

第4章 市場規模及預測

  • 重點
  • 市場促進因素與限制因素
  • 按藥物類別分類的趨勢
  • 各國具體趨勢

第5章 競爭情勢

  • 目前療法
    • 重點
    • 診斷和治療過程/演算法
    • 主要療法概述及KOL洞察
  • 新興療法
    • 重點
    • 值得關注的後期新療法—概述、市場上市預期和KOL洞察
    • 值得關注的早期研發管線

第6章：未滿足的需求與目標產品分析

  • 主要未滿足的需求以及透過新興療法實現的未來可能性
  • TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

簡介目錄

Alzheimer's Disease (AD) Market Outlook

Thelansis's "Alzheimer's Disease (AD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Alzheimer's Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Alzheimer's Disease (AD) Overview

Alzheimer's Disease (AD) is the foremost cause of dementia, accounting for approximately 60-80% of all dementia cases. It is a progressive neurodegenerative disorder characterized by cognitive decline, memory impairment, and functional deterioration, ultimately leading to complete dependency.

The disease is defined by three key pathological features within the brain:

1. Amyloid plaques - extracellular protein aggregates composed of amyloid-beta fragments

2. Neurofibrillary tangles (NFTs) - intracellular accumulations of hyperphosphorylated tau protein

3. Synaptic and neuronal loss - resulting in disruption of communication between neurons and progressive cognitive decline

These pathological changes distinguish AD from other forms of dementia such as Lewy body disease and cerebrovascular dementia, although coexisting pathologies may occur, a condition referred to as mixed dementia. AD primarily affects the elderly population, with risk increasing significantly with age. Clinically, the disease progresses from mild cognitive impairment (MCI) to moderate and severe dementia.

Recent advances have shifted the treatment paradigm from purely symptomatic management toward disease-modifying therapies (DMTs) targeting amyloid pathology, marking a significant transformation in the AD treatment landscape.

Key Highlights

  • The diagnosed Alzheimer's population in the United States is projected to grow significantly, increasing from 3.0 million in 2025 to 4.9 million by 2035, reflecting a strong growth trajectory (5%+ CAGR).
  • AD remains a high-burden chronic disease, with substantial clinical, economic, and caregiver impact.
  • Despite large patient numbers, early-stage diagnosis remains suboptimal, limiting timely intervention and uptake of disease-modifying therapies.
  • The treatment paradigm is shifting from: Symptomatic therapies (cholinesterase inhibitors, NMDA antagonists) toward Disease-modifying therapies targeting amyloid-beta pathways
  • Early-stage (MCI/mild AD) patients represent the primary target population for emerging therapies, driving segmentation and treatment prioritization.

Market Overview

  • The Alzheimer's market is undergoing a significant transformation, driven by the emergence and adoption of disease-modifying therapies.
  • The diagnosed patient pool is expanding at 5% CAGR, creating a large and growing addressable market of the US.
  • The Alzheimer's market in France is projected to grow from $27M in 2025 to $978M by 2035

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support
  • As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2025-2035)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market's trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

  • G8
    • United States
    • EU5
      • France
      • Germany
      • Italy
      • Spain
      • U.K.
    • Japan
    • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

  • Hoffmann-La Roche
  • Halia Therapeutics, Inc.
  • Novo Nordisk A/S
  • BeyondBio Inc.
  • Ono Pharmaceutical Co. Ltd
  • Eli Lilly and Company
  • Regeneration Biomedical, Inc.
  • Keymed Biosciences Co.Ltd
  • Amydis Inc.
  • ScandiBio Therapeutics AB
  • Karuna Therapeutics, Inc.
  • NSC-Therapeutics
  • Alzamend Neuro, Inc.
  • Annovis Bio Inc.
  • Bristol-Myers Squibb
  • NKGen Biotech, Inc.
  • Acumen Pharmaceuticals
  • Lexeo Therapeutics
  • Eisai Inc.
  • Cassava Sciences, Inc.
  • Merck Sharp & Dohme LLC
  • AriBio Co., Ltd.
  • Alector Inc.
  • Noah Pharmaceuticals, Inc.
  • Amylyx Pharmaceuticals Inc.
  • TauRx Therapeutics Ltd
  • Jiangsu Nhwa Pharmaceutical Co., Ltd.
  • AbbVie
  • Oligomerix, Inc
  • Life Molecular Imaging Ltd
  • Nuravax, Inc.
  • Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
  • Novartis Pharmaceuticals
  • Beijing Joekai Biotechnology LLC
  • Vigil Neuroscience, Inc.
  • Allyx Therapeutics
  • T3D Therapeutics, Inc.
  • GlaxoSmithKline
  • Atridia Pty Ltd.
  • Alnylam Pharmaceuticals
  • Shanghai Hengrui Pharmaceutical Co., Ltd.
  • Akeso
  • Medesis Pharma SA
  • Avid Radiopharmaceuticals
  • CereMark Pharma, LLC
  • Araclon Biotech S.L.
  • Luye Pharma Group Ltd.

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

  • Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

  • Key takeaways
  • Incidence / Prevalence
  • Diagnosed and Drug-Treated populations
  • Comorbidities
  • Other relevant patient segments

4. Market Size and Forecast

  • Key takeaways
  • Market drivers and constraints
  • Drug-class specific trends
  • Country-specific trends

5. Competitive Landscape

  • Current therapies
    • Key takeaways
    • Dx and Tx journey/algorithm
    • Key current therapies - profiles and KOL insights
  • Emerging therapies
    • Key takeaways
    • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
    • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)